The Evolving Diagnostic and Treatment Landscape of NTRK-Fusion-Driven Pediatric Cancers

Phase 1/1B trial to assess the activity of entrectinib in children and adolescents with recurrent or refractory solid tumors including central nervous system (CNS) tumors.

(2019) Giles W. Robinson et al.   JOURNAL OF CLINICAL ONCOLOGY

Activity of larotrectinib in TRK fusion cancer patients with brain metastases or primary central nervous system tumors.

(2019) Alexander E. Drilon et al.   JOURNAL OF CLINICAL ONCOLOGY

Resistance to TRK inhibition mediated by convergent MAPK pathway activation

(2019) Emiliano Cocco et al.   NATURE MEDICINE

Pan-Trk Immunohistochemistry Identifies NTRK Rearrangements in Pediatric Mesenchymal Tumors

(2018) Erin R. Rudzinski et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study

(2018) Theodore W Laetsch et al.   LANCET ONCOLOGY

Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children

(2018) Alexander Drilon et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Use of Neoadjuvant Larotrectinib in the Management of Children With Locally Advanced TRK Fusion Sarcomas

(2018) Steven G. DuBois et al.   CANCER

Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies

(2018) Justin Taylor et al.   JOURNAL OF CLINICAL INVESTIGATION

Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations

(2018) Alexander Drilon et al.   Cancer Discovery

Expanding the Spectrum of Pediatric NTRK-rearranged Mesenchymal Tumors

(2018) Jessica L. Davis et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

NTRK fusion-positive cancers and TRK inhibitor therapy

(2018) Emiliano Cocco et al.   Nature Reviews Clinical Oncology

Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children’s Oncology Group Study

(2017) Yael P. Mossé et al.   JOURNAL OF CLINICAL ONCOLOGY

Recurrent EML4–NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy

(2017) Alanna J Church et al.   MODERN PATHOLOGY

Identification of NTRK fusions in pediatric mesenchymal tumors

(2017) Dean Pavlick et al.   PEDIATRIC BLOOD & CANCER

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)

(2017) Alexander Drilon et al.   Cancer Discovery

A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion–Positive Solid Tumors

(2017) Alexander Drilon et al.   Cancer Discovery

What hides behind the MASC: clinical response and acquired resistance to entrectinib afterETV6-NTRK3identification in a mammary analogue secretory carcinoma (MASC)

(2016) A. Drilon et al.   ANNALS OF ONCOLOGY

Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model

(2016) Radhika Iyer et al.   CANCER LETTERS

Conservative strategy in infantile fibrosarcoma is possible: The European paediatric Soft tissue sarcoma Study Group experience

(2016) Daniel Orbach et al.   EUROPEAN JOURNAL OF CANCER

Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications

(2016) E. Ardini et al.   MOLECULAR CANCER THERAPEUTICS

Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer

(2016) J. F. Gainor et al.   Cancer Discovery

Trk inhibitor attenuates the BDNF/TrkB-induced protection of neuroblastoma cells from etoposidein vitroandin vivo

(2015) Zhijie Li et al.   CANCER BIOLOGY & THERAPY

Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer

(2015) M. Russo et al.   Cancer Discovery

An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101

(2015) R. C. Doebele et al.   Cancer Discovery

TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts

(2014) Jamie L. Croucher et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study

(2013) Yael P Mossé et al.   LANCET ONCOLOGY

The integrated landscape of driver genomic alterations in glioblastoma

(2013) Veronique Frattini et al.   NATURE GENETICS

Acquired Resistance to Crizotinib from a Mutation in CD74–ROS1

(2013) Mark M. Awad et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers

(2012) R. Katayama et al.   Science Translational Medicine

Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study

(2011) Jane E. Minturn et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

The selective Trk inhibitor AZ623 inhibits brain-derived neurotrophic factor-mediated neuroblastoma cell proliferation and signaling and is synergistic with topotecan

(2010) Peter E. Zage et al.   CANCER

EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors

(2010) Young Lim Choi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Trk Receptor Expression and Inhibition in Neuroblastomas

(2009) G. M. Brodeur et al.   CLINICAL CANCER RESEARCH

Rearrangements of NTRK1 gene in papillary thyroid carcinoma

(2009) A. Greco et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway

(2009) K. Thress et al.   MOLECULAR CANCER THERAPEUTICS

Novel missense, insertion and deletion mutations in the neurotrophic tyrosine kinase receptor type 1 gene (NTRK1) associated with congenital insensitivity to pain with anhidrosis

(2008) Kathrin Huehne et al.   NEUROMUSCULAR DISORDERS

Neurotrophin receptor expression in human primary retinoblastomas and retinoblastoma cell lines

(2007) Harald Stephan et al.   PEDIATRIC BLOOD & CANCER